Research Round Up Podcasts: Central Nervous System Tumors and Head and Neck Cancer

Research Round Up Podcast Series
August 9, 2016
Claire Smith, ASCO staff

Cancer is a worldwide concern, and the ASCO Annual Meeting brings together researchers from all over the world to share information and advance our understanding of cancer and how to treat it. These 2 Research Round Up podcasts with Cancer.Net Associate Editors Susan Chang, MD, and Ezra Cohen, MD, FRCPC, show the importance of this international effort.

“Multidisciplinary and international collaboration” in central nervous system tumors

Dr. Chang of the University of California, San Francisco, discusses the wide-ranging research that was presented on central nervous system tumors, share on twitter including new research on brain metastases (pdf) and research into ways to improve outcomes for children with central nervous system tumors, such as medulloblastoma and ependymoma. Dr. Chang also discusses the new World Health Organization (WHO) classifications for central nervous system tumors and what this new classification system means for patients, as well as new advances in immunotherapy.  

Read a full transcript of this podcast.

Research highlights in head and neck cancer

Dr. Cohen from the University of California, San Diego Moores Cancer Center, discusses new research on head and neck cancer: share on twitter 

  • Several studies on immunotherapy drugs nivolumab (Yervoy) and pembrolizumab (Keytruda) show promising results for people with recurrent metastatic head and neck cancer [2:27].

  • Two studies compared induction chemotherapy, or chemotherapy given before radiation therapy, to the current standard of care for people with locally advanced head and neck cancer, which is chemotherapy and radiation given at the same time [6:52].

  • A study that looked at adding gemcitabine (Gemzar) to cisplatin (Platinol) to treat people with nasopharyngeal cancer may lead to a new standard of care [8:02].

  • Combining the targeted therapy buparlisib with paclitaxel (Abraxane) shows promising results in people with recurrent metastatic head and neck cancer and may lead to new avenues of research [9:37].

Read a full transcript of this podcast.

These are prerecorded audio podcasts. They can be listened to online or downloaded to your computer. For more information, visit the Cancer.Net podcast page.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.